Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Allogene Therapeutics history
Allogene Therapeutics company history timeline
He is a Co-Founder and Partner of Vida Ventures, LLC, a life science investment firm, and was a Co-Founder and Director of Kite Pharma, where he served on the Board of Directors from inception until its acquisition by Gilead Sciences in 2017.
Recognizing the clinical benefits, in 2017, the US Food and Drug Administration (FDA) approved 2 autologous CAR T cell therapies for patients with certain types of hematologic cancers: relapsed or refractory acute lymphoblastic leukemia and relapsed or refractory large B cell lymphoma.
Barbra joined Allogene as Chief Scientific Officer in April 2018 when the company acquired the allogeneic cell therapy assets from Pfizer.
Doctor Forman was recognized by the American Society for Blood and Marrow Transplantation as the 2019 E. Donnall Thomas Lecturer, and awarded the 2019 DKMS Mechtild Harf Science Award.
At UroGen, Liz spearheaded the 2020 approval of Jelmyto® for the treatment of low-grade upper tract urothelial carcinoma.
Rate Allogene Therapeutics' efforts to communicate its history to employees.
Allogene Therapeutics jobs
Do you work at Allogene Therapeutics?
Does Allogene Therapeutics communicate its history to new hires?
Allogene Therapeutics competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Fate Therapeutics | 2007 | $13.6M | 104 | 9 |
| Atara Biotherapeutics | 2012 | $128.9M | 578 | - |
| Poseida Therapeutics | 2014 | $64.7M | 200 | - |
| BioTime | 1990 | $3.4M | 101 | - |
| Eureka Therapeutics | 2006 | $500,000 | 50 | - |
| Adaptimmune | 2008 | $178.0M | 452 | - |
| TCR² Therapeutics | 2015 | $661.1M | 118 | - |
| Cabaletta Bio | 2017 | $1.6M | 20 | 11 |
| G1 Therapeutics | 2008 | $82.5M | 148 | 2 |
| Arcellx | 2015 | $107.9M | 1 | 54 |
Allogene Therapeutics history FAQs
Zippia gives an in-depth look into the details of Allogene Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Allogene Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Allogene Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Allogene Therapeutics. The data presented on this page does not represent the view of Allogene Therapeutics and its employees or that of Zippia.
Allogene Therapeutics may also be known as or be related to ALLOGENE THERAPEUTICS, INC., Allogene Therapeutics, Allogene Therapeutics Inc, Allogene Therapeutics Inc. and Allogene Therapeutics, Inc.